首页> 外文OA文献 >Rationale and design issues of the randomized intervention for children with vesicoureteral reflux (RIVUR) study
【2h】

Rationale and design issues of the randomized intervention for children with vesicoureteral reflux (RIVUR) study

机译:儿童膀胱输尿管反流(RIVUR)研究的随机干预的原理和设计问题

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE. Our goal is to determine if antimicrobial prophylaxis with trimethoprim/sulfamethoxazole prevents recurrent urinary tract infections and renal scarring in children who are found to have vesicoureteral reflux after a first or second urinary tract infection. DESIGN, PARTICIPANTS, AND METHODS. The Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study is a double-blind, randomized, placebo-controlled trial. Six hundred children aged 2 to 72 months will be recruited from both primary and subspecialty care settings at clinical trial centers throughout North America. Children who are found to have grades I to IV vesicoureteral reflux after the index febrile or symptomatic urinary tract infection will be randomly assigned to receive daily doses of either trimethoprim/sulfamethoxazole or placebo for 2 years. Scheduled follow-up contacts include in-person study visits every 6 months and telephone interviews every 2 months. Biospecimens (urine and blood) and genetic specimens (blood) will be collected for future studies of the genetic and biochemical determinants of vesicoureteral reflux, recurrent urinary tract infection, renal insufficiency, and renal scarring. RESULTS. The primary outcome is recurrence of urinary tract infection. Secondary outcomes include time to recurrent urinary tract infection, renal scarring (assessed by dimercaptosuccinic acid scan), treatment failure, renal function, resource utilization, and development of antimicrobial resistance in stool flora. CONCLUSIONS. The RIVUR study will provide useful information to clinicians about the risks and benefits of prophylactic antibiotics for children who are diagnosed with vesicoureteral reflux after a first or second urinary tract infection. The data and specimens collected over the course of the study will allow researchers to better understand the pathophysiology of recurrent urinary tract infection and its sequelae. Copyright © 2008 by the American Academy of Pediatrics.
机译:目的。我们的目标是确定在首次或第二次尿路感染后发现有膀胱输尿管反流的儿童中,甲氧苄啶/磺胺甲基异恶唑的抗菌药物预防措施是否能预防尿路反复感染和肾脏瘢痕形成。设计,参与者和方法。儿童血管输尿管反流的随机干预研究(RIVUR)是一项双盲,随机,安慰剂对照试验。在整个北美的临床试验中心,将从初级和专科医疗机构招募的600名2至72个月的儿童。发现发热或症状性尿路感染后I至IV级膀胱输尿管反流的儿童,将被随机分配接受每日剂量的甲氧苄啶/磺胺甲恶唑或安慰剂治疗,为期两年。计划的后续联系包括每6个月的面对面学习访问和每2个月的电话访问。将收集生物标本(尿液和血液)和遗传标本(血液),用于将来研究膀胱输尿管反流,复发性尿路感染,肾功能不全和肾瘢痕形成的遗传和生化决定因素。结果。主要结局是尿路感染的复发。次要结果包括复发尿路感染的时间,肾瘢痕形成(通过二巯基琥珀酸扫描评估),治疗失败,肾功能,资源利用以及粪便菌群中的抗菌素耐药性发展。结论。 RIVUR研究将为临床医生提供有用的信息,帮助他们了解在第一次或第二次尿路感染后被诊断患有膀胱输尿管反流的儿童的预防性抗生素的风险和益处。在研究过程中收集的数据和标本将使研究人员能够更好地了解复发性尿路感染的病理生理学及其后遗症。美国儿科学会版权所有©2008。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号